Drug
Tenalisib clinical trials
Also written RP6530.
- studies test it
- 11
- open now
- 1
- in phase 3
- 0
- first study started
- 2013
Keep track of what changes. Save the tenalisib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 3 |
| 2019 | 2 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Rhizen Pharmaceuticals SA (11)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tenalisib is read from its arms, and is right about nine times in ten.
Testing it · 11
- Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)RecruitingPhase 2Rhizen Pharmaceuticals SANCT06189209Written as Tenalisib
- Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)CompletedPhase 2Rhizen Pharmaceuticals SANCT04204057Written as Tenalisib
- Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast CancerCompletedPhase 2Rhizen Pharmaceuticals SANCT05021900Written as Tenalisib 800mg
- Compassionate Use Study of Tenalisib (RP6530)CompletedPhase 1/2Rhizen Pharmaceuticals SANCT03711604Written as Tenalisib
- Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell LymphomaCompletedPhase 1/2Rhizen Pharmaceuticals SANCT03770000Written as Tenalisib
- Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCLWithdrawnPhase 2Rhizen Pharmaceuticals SANCT05239910Written as Tenalisib
- Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)CompletedPhase 2Rhizen Pharmaceuticals SANCT03711578Written as Tenalisib,
- Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell LymphomaCompletedPhase 1Rhizen Pharmaceuticals SANCT02567656Written as RP6530
- Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHLTerminatedPhase 1Rhizen Pharmaceuticals SANCT03471351Written as Tenalisib
- To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy VolunteersCompletedPhase 1Rhizen Pharmaceuticals SANCT02690727Written as RP6530
- Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological MalignanciesCompletedPhase 1Rhizen Pharmaceuticals SANCT02017613Written as RP6530
Codes
What other systems call tenalisib · ClinicalTrials.gg INT001309
- MeSH (NLM) C000706530tenalisibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 2261HH611HTENALISIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27253617tenalisibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C113433TenalisibOne source FDA
- DrugBank DB15295One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000706530 | tenalisib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 2261HH611H | TENALISIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27253617 | tenalisib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C113433 | Tenalisib | One source FDA |
| DrugBank | DB15295 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.